Showing 2251-2260 of 2652 results for "".
- Zeiss Celebrates 175th Anniversary in 2021https://modernod.com/news/zeiss-celebrates-175th-anniversary-in-2021/2479194/Zeiss’ success story began 175 years ago, in a small workshop. On November 17, 1846, young mechanic Carl Zeiss opened his workshop for precision mechanics and optics in Jena, thus laying the foundation for what would become today’s global technology player Zeiss. Zeiss went on to join
- Novartis: Phase 3 Beovu Data Show Potential for Fluid Resolution in More DME Patients With Fewer Injections Versus Aflibercepthttps://modernod.com/news/novartis-phase-3-beovu-data-show-potential-for-fluid-resolution-in-more-dme-patients-with-fewer-injections-versus-aflibercept/2479150/Novartis announced positive 1-year results of the phase III KESTREL and KITE studies, evaluating the efficacy and safety of Beovu (brolucizumab-dbll) 6 mg in diabetic macular edema (DME). Both studies met their primary endpoints of noninferiority in change in best corrected visual acuity (
- Johnson & Johnson Vision Presents New Myopia, Cataract, Refractive, and Meibomian Gland Dysfunction Data at ARVO 2021https://modernod.com/news/johnson-johnson-vision-presents-new-myopia-cataract-refractive-and-meibomian-gland-dysfunction-data-at-arvo-2021/2479152/Johnson & Johnson Vision will present nearly 30 posters and papers of research data on myopia, IOL, phacoemulsification, refractive, and meibomian gland dysfunction at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. This year’s premier vision research meet
- Market Scope: Backlog of 6 Million Cataract Surgeries Will Help Drive IOL Market Through 2026https://modernod.com/news/backlog-of-6-million-cataract-surgeries-will-help-drive-iol-market-through-2026/2479127/Pandemic-impacted 2020 led to a backlog of more than 6 million cataract surgeries globally, as procedures declined 25 percent to 22 million, the lowest number since 2010, mainly due to COVID-related shutdowns in elective surgeries, according to a Market Scope report. The amount of time it
- Market Scope: US Cataract Pharmaceuticals Evolve in Drug Deliveryhttps://modernod.com/news/market-scope-us-cataract-pharmaceuticals-evolve-in-drug-delivery/2479107/US cataract surgeons showed a preference for incremental improvement in drug delivery over revolutionary change in the first full year for three new corticosteroid products to manage inflammation and pain after cataract surgery, according to a Market Scope report. The products hit the mark
- EyeCare Partners Promotes David Clark to Chief Executive Officerhttps://modernod.com/news/eyecare-partners-promotes-david-clark-to-chief-executive-officer/2479099/EyeCare Partners LLC announced the promotion of David A. Clark to chief executive officer, effective immediately. Mr. Clark joined EyeCare Partners as president in July 2020 after 20 years with MEDNAX Inc., where he was most recently ch
- Katena Products Acquires Ophthalmic Instrument Maker Asicohttps://modernod.com/news/katena-products-acquires-ophthalmic-instrument-maker-asico/2479080/Katena Products announced it has purchased ophthalmic surgical instrument maker Asico. Terms of the deal were not disclosed Asico’s product range encompasses more 1,500 items, including stainless steel and titanium instruments, single-use cannulas and blades, and diamond knives.
- Allergan Launches New Consumer Ad Campaign for Restasishttps://modernod.com/news/allergan-launches-new-consumer-ad-campaign-for-restasis/2479065/Allergan announced it is launching a direct-to-consumer (DTC) broadcast TV advertising campaign for Restasis (cyclosporine ophthalmic emulsion) 0.05%, launching April 2021. Restasis has been FDA approved for 17 years and is the #1 dispensed branded eye drop, prescribed
- David R. Guyer, MD, to Step Down from Iveric Bio Board to Rejoin Venture Fundhttps://modernod.com/news/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund/2479050/Iveric bio announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bio’s 2021 Annual Stockholder Meeting scheduled to be held on May 19, 2021. Dr. Guyer has served as the Chairman of Iveric’
- Johnson & Johnson Begins Testing COVID-19 Vaccine in Adolescentshttps://modernod.com/news/johnson-johnson-begins-testing-covid-19-vaccine-in-adolescents/2479045/Johnson & Johnson announced that it has begun vaccinating adolescent participants in an ongoing phase 2a trial of its COVID-19 vaccine candidate Ad26.COV2.S. The study, which got under way last September, was initially designed to evaluate single- and two-dose regimens of the vaccine in healt